Additionally, ADCT-701, an antibody-drug conjugate currently in an ongoing phase I clinical trial (NCT06041516) for adult patients with neuroendocrine tumors, has demonstrated effectiveness in targeting and killing DLK1-positive neuroblastoma cells in vivo (84, 85). The gene discussed is DLK1; the disease is neuroblastoma.